Syncona to invest $25m in Autolus Therapeutics IPO
Healthcare company investor Syncona noted that portfolio company and leukaemia treatment developer Autolus Therapeutics had priced a US initial public offering, for proceeds of around...
Wed, 10/02/2021 - 07:55